Suppression of Diabetic Retinopathy with Angiopoietin-1
Antonia M. Joussen(Humboldt-Universität zu Berlin), Anthony P. Adamis(Massachusetts Eye and Ear Infirmary), Akitaka Tsujikawa(Kyoto University), Ella Ioffe(Regeneron (United States)), Sven–Erik Bursell(Joslin Diabetes Center), Wenying Qin(Massachusetts Eye and Ear Infirmary), George D. Yancopoulos(Regeneron (United States)), Stanley J. Wiegand¶(Regeneron (United States)), Qingwen Xu(Massachusetts Eye and Ear Infirmary), John S. Rudge(Regeneron (United States)), Y Moromizato(Massachusetts Eye and Ear Infirmary), Vassiliki Poulaki(Massachusetts Eye and Ear Infirmary), Tamim Qaum(Harvard University)
Cited by 201
Related Papers
Vascular-specific growth factors and blood vessel formation
|Nature|2000|3.7k
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
|New England Journal of Medicine|2016|2k
VEGF-Trap: A VEGF blocker with potent antitumor effects
|Proceedings of the National Academy of Sciences|2002|1.7k
Regulation of the Germinal Center Response by MicroRNA-155
|Science|2007|1.5k
Angiopoietin-1 protects the adult vasculature against plasma leakage
|Nature Medicine|2000|1.3k